Circio Holding ASA

Circio Holding ASA: Requested Conversion of Convertible Bonds

Reference is made to Circio Holding ASA's (the "Company") outstanding

convertible bonds as issued to Atlas Special Opportunities, LLC ("Atlas")

under the Investment Agreement entered into between Atlas and the Company in

March 2023.

Atlas has, by a notice of conversion, requested conversion of convertible

bonds with a nominal value of NOK 2,000,000 which, pursuant to the bond terms,

are convertible into 3,265,661 new shares in the Company at a conversion price

of NOK 0.6124.

The Company's share capital will accordingly be increased by NOK 1,959,396.60

by the issuance of 3,265,661 new shares upon completion of the conversion by

registration of the share capital increase in the Norwegian Register of

Business Enterprises (Nw.: Foretaksregisteret). Following the conversion, the

Company's total share capital will be NOK 63,305,046.60 divided into

105,508,411 shares, each with a nominal value of NOK 0.60.

For further information, please contact:

Erik Digman Wiklund, CEO

Phone: +47 413 33 536

Lubor Gaal, CFO

Phone: +34 683 34 3811

About Circio

Building circular RNA expression systems for enhanced gene and cell therapies

Circio Holding ASA is a biotechnology company developing powerful circular RNA

vector expression technology for next generation nucleic acid medicine.

Circio has established a unique circular RNA (circRNA) vector expression

technology for next generation RNA, DNA and viral therapeutics. The

proprietary circVec platform is based on a modular genetic cassette design for

efficient biogenesis of multifunctional circRNA inside cells. The circVec

platform has applications in multiple therapeutic settings, including genetic

medicine, cell therapy and chronic disease. It has demonstrated over 70-fold

prolonged RNA half-life and up to 15-fold enhanced protein expression vs.

conventional mRNA vector systems in vivo, and has the potential to become a

new gold-standard protein expression technology. The circRNA R&D activities

are being conducted by the wholly owned subsidiary Circio AB in Stockholm,

Sweden.

In parallel, Circio is continuing to develop its legacy immuno-oncology

program, TG01, through cost-efficient external academic and industry

collaborations. TG01 targets RAS-mutated cancers and is being tested in two

clinical trials in Norway and the USA. TG01 is a therapeutic peptide vaccine

adjuvanted by STIMULON QS-21 licensed from Agenus Inc.

AI Terminal